CJC-1295 vs Desmopressin
Overview
CJC-1295 is primarily a performance & growth peptide, while Desmopressin is used for hormonal.
This page compares CJC-1295 and Desmopressin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CJC-1295 | Desmopressin | |
|---|---|---|
| Category | Performance & Growth | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 1-2 mg | 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) |
| Frequency | weekly | Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia) |
| Reported benefits | Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density | central diabetes insipidus management, primary nocturnal enuresis in children, nocturia due to nocturnal polyuria, perioperative hemostasis in mild hemophilia A, hemostasis in Type I von Willebrand disease, management of polyuria following head trauma or pituitary surgery |
| Reported side effects | Water retention, joint pain, potential insulin resistance with prolonged use | hyponatremia (boxed warning), headache, facial flushing, nausea, abdominal cramps, fluid retention, hypotension, reflex tachycardia, hypertension, tachyphylaxis with repeated dosing, rare anaphylaxis |
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while Desmopressin falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. Desmopressin: FDA-approved.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). Desmopressin is typically dosed at 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) (Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia)).
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and Desmopressin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CJC-1295 and Desmopressin?
- CJC-1295 is primarily a performance & growth peptide, while Desmopressin is used for hormonal. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas Desmopressin is FDA-approved for one or more indications.
- What is CJC-1295 used for?
- Growth hormone, muscle mass, fat loss.
- What is Desmopressin used for?
- Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders.
- Can you take CJC-1295 and Desmopressin together?
- Some users combine peptides within a single protocol, but stacking CJC-1295 and Desmopressin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CJC-1295 or Desmopressin FDA-approved?
- CJC-1295 is not FDA-approved; generally classified as a research compound. Desmopressin is FDA-approved for one or more indications.
Read the full articles
- CJC-1295 — full monograph: mechanism, research, dosing & references
- Desmopressin — full monograph: mechanism, research, dosing & references